Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing. Placing P140K MGMT, a gene that has been created in the laboratory into bone marrow making the bone more resistant to chemotherapy, allowing intra-patient dose escalation which kills more tumor cells while allowing bone marrow to survive.

Participants needed: 16
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Leland MethenyUpdated: Nov 21, 2025Locations: 1
Eligibility criteria

Patients with histologically confirmed, newly diagnosed, supratentorial glioblas... [+16]

Any known medical or hereditary condition associated with immunosuppression;orot... [+9]

Status: Recruiting

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT. Participants will: * Partake in exams, tests, and procedures as part of usual cancer care. * Partake in conditioning, which is the treatment that is given before a transplant. * Have a cord blood transplant. * Partake in radiation following the transplant.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Leland MethenyUpdated: Jun 4, 2025Locations: 1
Eligibility criteria

Antecedent hematological disease (e.g., myelodysplasia (MDS)) [+28]

Creatinine clearance < 50ml/min [+12]

Status: Recruiting

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.

Participants needed: 44
Trial details
Phase: Phase 1, Phase 2Age: 16-75Biological sex: AllType: InterventionalSponsor: Leland MethenyUpdated: Jun 5, 2025Locations: 7
Eligibility criteria

Diagnosis of CD22-positive Acute Lymphoblastic Leukemia [+29]

Patients with clinical evidence of disease progression prior to enrollment [+17]